FDA Clinical Practices Oversight Will Move To Risk-Based Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will begin reviewing how it regulates clinical trial research within a year, FDA Good Clinical Practice Director Lepay says at DIA annual meeting. Inspections will move from a "rote" approach towards a risk-based method modeled on the GMP risk management initiative.